Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis

Clinical Therapeutics

Volumn 38, Issue 12, 2016, Pages 2642-2651

  McAdam Marx, Carrie ^a   Nguyen, Hiep ^b   Schauerhamer, Marisa B ^a   Singhal, Mukul ^a   Unni, Sudhir ^a   Ye, Xiangyang ^a   Cobden, David ^b  

^a UNIVERSITY OF UTAH   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

diabetes mellitus; exenatide; glycemic control; liraglutide; observational study; weight

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; PRAMLINTIDE; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; AGONISTS; ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; VENOMS;

EID: 85006835818     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.11.003     Document Type: Article

References (13)

1. 1 Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. 2014, CDC, Atlanta, Georgia http://www.cdc.gov/diabetes/pubs/statsreport14.htm Accessed June 14, 2014.
2. 2 American Diabetes Association. Approaches to Glycemic Treatment. Diabetes Care 38:Supplement 1 (2015), S41–S48.
3. 3 Garber, A.J., Abrahamson, M.J., Barzilay, J.I., et al. Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract 21 (2015), 438–447.
4. 4 Buse, J.B., Bergenstal, R.M., Glass, L.C., et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154 (2011), 103–112.
5. 5 Wubben, D.P., Vivian, E.M., Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy 28 (2008), 421–436.
6. 6 Salvo, M.C., Brooks, A.M., Glycemic control and preventive care measures of indigent diabetes patients within a pharmacist-managed insulin titration program vs standard care. Ann Pharmacother 46 (2012), 29–34.
7. 7 Scott, L.J., Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs 72 (2012), 1679–1707.
8. 8 Dharmalingam, M., Sriram, U., Baruah, M.P., Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab 15 (2011), 9–17.
9. 9 Buse, J.B., Nauck, M., Forst, T., et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381 (2013), 117–124.
10. 10 Johnston, S.S., Nguyen, H., Felber, E., et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther 31 (2014), 1119–1133.
11. 11 Saunders, W.B., Nguyen, H., Kalsekar, I., Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study. Diabetes Metab Syndr Obes 9 (2016), 217–223.
12. 12 Charlson, M.E., Charlson, R.E., Peterson, J.C., et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 61 (2008), 1234–1240.
13. 13 Scott, D.A., Boye, K.S., Timlin, L., et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 15 (2013), 213–223.